JP2020530273A5 - - Google Patents

Download PDF

Info

Publication number
JP2020530273A5
JP2020530273A5 JP2019572486A JP2019572486A JP2020530273A5 JP 2020530273 A5 JP2020530273 A5 JP 2020530273A5 JP 2019572486 A JP2019572486 A JP 2019572486A JP 2019572486 A JP2019572486 A JP 2019572486A JP 2020530273 A5 JP2020530273 A5 JP 2020530273A5
Authority
JP
Japan
Prior art keywords
host cell
sequence
cell according
leishmania
transferase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019572486A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020530273A (ja
JP7437162B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2018/067494 external-priority patent/WO2019002512A2/en
Publication of JP2020530273A publication Critical patent/JP2020530273A/ja
Publication of JP2020530273A5 publication Critical patent/JP2020530273A5/ja
Priority to JP2023104857A priority Critical patent/JP2023134519A/ja
Application granted granted Critical
Publication of JP7437162B2 publication Critical patent/JP7437162B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019572486A 2017-06-30 2018-06-28 改変されかつ完全に機能カスタマイズされた糖タンパク質 Active JP7437162B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023104857A JP2023134519A (ja) 2017-06-30 2023-06-27 改変されかつ完全に機能カスタマイズされた糖タンパク質

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762527466P 2017-06-30 2017-06-30
US62/527,466 2017-06-30
PCT/EP2018/067494 WO2019002512A2 (en) 2017-06-30 2018-06-28 GLYCOPROTEINS CUSTOMIZED FROM ENGINEERING AND FULLY FUNCTIONAL

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023104857A Division JP2023134519A (ja) 2017-06-30 2023-06-27 改変されかつ完全に機能カスタマイズされた糖タンパク質

Publications (3)

Publication Number Publication Date
JP2020530273A JP2020530273A (ja) 2020-10-22
JP2020530273A5 true JP2020530273A5 (https=) 2021-08-12
JP7437162B2 JP7437162B2 (ja) 2024-02-22

Family

ID=62815031

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019572486A Active JP7437162B2 (ja) 2017-06-30 2018-06-28 改変されかつ完全に機能カスタマイズされた糖タンパク質
JP2023104857A Pending JP2023134519A (ja) 2017-06-30 2023-06-27 改変されかつ完全に機能カスタマイズされた糖タンパク質

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023104857A Pending JP2023134519A (ja) 2017-06-30 2023-06-27 改変されかつ完全に機能カスタマイズされた糖タンパク質

Country Status (7)

Country Link
US (2) US11913051B2 (https=)
EP (1) EP3645732A2 (https=)
JP (2) JP7437162B2 (https=)
KR (2) KR102711998B1 (https=)
CN (3) CN119639577A (https=)
AU (1) AU2018294504B2 (https=)
WO (1) WO2019002512A2 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019002512A2 (en) 2017-06-30 2019-01-03 Limmatech Biologics Ag GLYCOPROTEINS CUSTOMIZED FROM ENGINEERING AND FULLY FUNCTIONAL
WO2019234021A1 (en) 2018-06-04 2019-12-12 Limmatech Biologics Ag Glycoengineered monoclonal antibody
CN111518736B (zh) 2019-10-24 2022-04-15 华熙生物科技股份有限公司 一种高效合成高纯度透明质酸及其寡聚糖的重组谷氨酸棒状杆菌
WO2021140143A1 (en) 2020-01-07 2021-07-15 Limmatech Biologics Ag Glycoengineering using leishmania cells
CA3166728A1 (en) * 2020-01-07 2021-07-15 Limmatech Biologics Ag Engineered leishmania cells
CA3181572A1 (en) * 2020-06-08 2021-12-16 Paul STABACH Compositions and methods for treating and/or preventing coagulopathy and/or sepsis in patients suffering from bacterial and/or viral infections
WO2022053673A1 (en) 2020-09-14 2022-03-17 Limmatech Biologics Ag Fab sialylation of antibodies
US20250281626A1 (en) 2021-03-23 2025-09-11 Glycoera Ag Mannose 3 glycan-mediated protein degradation
AU2022246021A1 (en) 2021-03-23 2023-10-05 Glycoera Ag Glycan-mediated protein degradation
EP4330383A1 (en) * 2021-04-29 2024-03-06 Novartis AG Hypersialylating cells
JP2025534987A (ja) 2022-09-28 2025-10-22 グリコエラ アーゲー グリカン媒介タンパク質分解
AU2024206743A1 (en) 2023-01-05 2025-08-14 Glycoera Ag Glycoengineered polypeptides targeting anti-neutrophil autoantibodies and uses thereof
WO2024147113A1 (en) 2023-01-05 2024-07-11 Glycoera Ag Glycoengineered polypeptides targeting anti-podocyte autoantibodies and uses thereof
US20260055191A1 (en) 2023-01-05 2026-02-26 Glycoera Ag Glycoengineered polypeptides targeting immunoglobulin a and complexes comprising the same
WO2024218743A1 (en) 2023-04-21 2024-10-24 Glycoera Ag Multi-functional molecules comprising glycans and uses thereof
WO2025215516A1 (en) 2024-04-08 2025-10-16 Glycoera Ag Glycoengineered polypeptides targeting igg4 autoantibodies and uses thereof
WO2025226309A1 (en) * 2024-04-26 2025-10-30 Rock Biomedical Inc. Engineered glycoprotein population and uses thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2388151C (en) * 1999-11-05 2010-01-12 Jena Bioscience Gmbh Protein expression systems for non-pathogenic kinetoplastidae
US7863020B2 (en) 2000-06-28 2011-01-04 Glycofi, Inc. Production of sialylated N-glycans in lower eukaryotes
CN107119095B (zh) * 2008-01-03 2022-07-05 康乃尔研究基金会有限公司 原核生物中的糖基化蛋白表达
WO2010038802A1 (ja) 2008-10-01 2010-04-08 旭硝子株式会社 宿主、形質転換体およびその製造方法、ならびにｏ－グリコシド型糖鎖含有異種蛋白質の製造方法
JP2015502144A (ja) * 2011-10-28 2015-01-22 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Ａｌｇ３の発現を欠損したピキア・パストリス（Ｐｉｃｈｉａｐａｓｔｒｉｓ）株中のＮ−グリカン占有率を増加させ、ハイブリッドＮ−グリカンの産生を低減させる方法
CA3006400A1 (en) 2015-11-30 2017-06-08 Limmatech Biologics Ag Methods of producing glycosylated proteins
WO2019002512A2 (en) 2017-06-30 2019-01-03 Limmatech Biologics Ag GLYCOPROTEINS CUSTOMIZED FROM ENGINEERING AND FULLY FUNCTIONAL
WO2021140143A1 (en) 2020-01-07 2021-07-15 Limmatech Biologics Ag Glycoengineering using leishmania cells
CA3166728A1 (en) 2020-01-07 2021-07-15 Limmatech Biologics Ag Engineered leishmania cells
WO2022053673A1 (en) 2020-09-14 2022-03-17 Limmatech Biologics Ag Fab sialylation of antibodies

Similar Documents

Publication Publication Date Title
JP2020530273A5 (https=)
JP7684310B2 (ja) Ｌｅｉｓｈｍａｎｉａ細胞を使用する糖鎖修飾改変
JP7720307B2 (ja) 操作されたＬｅｉｓｈｍａｎｉａ細胞
Walsh Post-translational modifications of protein biopharmaceuticals
JP7437162B2 (ja) 改変されかつ完全に機能カスタマイズされた糖タンパク質
ES2952405T3 (es) Parejas de fusión para la producción de péptidos
ES2664328T3 (es) Variantes de albúmina
US20120045816A1 (en) Novel Glycosylated Polypeptides
JP2019502401A5 (https=)
WO2024068768A1 (en) Glycoengineering using leishmania cells
KR102593407B1 (ko) 개선된 발효 공정
US20140199286A1 (en) Lyophilization process
Walsh Post-translational modifications in the context of therapeutic proteins: An introductory overview
EP3752592B1 (en) Buffer formulation method and system
US20180162903A1 (en) Method for the reduction of viral titer in pharmaceuticals
US20180094231A1 (en) Reactor Surface Finish Remediation
WO2022192687A1 (en) Synthetic promoters for gene therapy and protein expression
Jagschies Appendix 3—Marketed Biotherapeutics
JP2026067872A (ja) 改変されかつ完全に機能カスタマイズされた糖タンパク質